Anyang Sun

Title: Innovations of Anyang Sun in Sigma-2 Receptor Inhibition

Introduction

Anyang Sun is a notable inventor based in Shanghai, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target sigma-2 receptors. His work has implications for therapeutic advancements in treating various diseases.

Latest Patents

Anyang Sun holds a patent for an isoindol-sulfilimine compound, which is utilized as a sigma-2 receptor inhibitor. This invention relates to the preparation and application of the compound, which effectively inhibits sigma-2 receptor activity. By binding to the sigma-2 receptor, the compound regulates the receptor complex, leading to the destabilization of adjacent Aβ oligomers at the synapse. This mechanism has potential applications in developing new therapeutic drugs for tumor and neurodegenerative diseases.

Career Highlights

Anyang Sun is affiliated with the Shanghai University of Medicine & Health Sciences. His research focuses on innovative approaches to drug development, particularly in the context of neurodegenerative disorders. His patent reflects his commitment to advancing medical science through innovative solutions.

Collaborations

Anyang Sun has collaborated with notable colleagues, including Xiuhong Lu and Gang Huang. Their combined expertise contributes to the advancement of research in the field of medicinal chemistry.

Conclusion

Anyang Sun's work exemplifies the intersection of innovation and medical research, particularly through his patented isoindol-sulfilimine compound. His contributions have the potential to lead to significant advancements in therapeutic options for serious health conditions.